Русский
Evaluation of the efficacy of silodosin 8 mg in comorbid patients with LUTS/BPH
DOI: https://dx.doi.org/10.18565/urology.2022.6.36-40
A.A. Zimichev, D.O. Gusev, D.Yu. Lukyanova
1) Department of Urology of FGBOU VO Samara State Medical University, Samara, Russia; 2) Department of Surgical Diseases No. 2 of REAVIZ Medical University
Introduction. According to domestic and foreign publications, benign prostatic hyperplasia (BPH) is one of the most common urological diseases among older men, which prevalence reaches 50% by the age of 60.
Aim. To analyze the efficiency of the use of the alpha1-blocker silodosin at a dose of 8 mg a day in comorbid patients with lower urinary tract symptoms (LUTS), associated with BPH.
Materials and methods. A total of 197 comorbid patients with LUTS/BPH were included in the study. All men underwent a standard examination. They were divided into 2 groups without differences in baseline parameters. In the main group (n=100) patients received silodosin at a dose of 8 mg, while in the control group 97 men did not receive any drug therapy for LUTS.
Discussion. There were significant differences between groups in the total IPSS score, postvoid residual (ml), maximum urine flow rate (ml/s), patient satisfaction with treatment efficacy based on the TS-VAS visual analogue scale (total score). However, we didn’t find significant differences in rate of cardiovascular side effects between the groups.
Conclusions. Treatment of comorbid patients with LUTS/BPH with silodosin at a dose of 8 mg results in significant improvement and is not associated with cardiovascular adverse events.
Aim. To analyze the efficiency of the use of the alpha1-blocker silodosin at a dose of 8 mg a day in comorbid patients with lower urinary tract symptoms (LUTS), associated with BPH.
Materials and methods. A total of 197 comorbid patients with LUTS/BPH were included in the study. All men underwent a standard examination. They were divided into 2 groups without differences in baseline parameters. In the main group (n=100) patients received silodosin at a dose of 8 mg, while in the control group 97 men did not receive any drug therapy for LUTS.
Discussion. There were significant differences between groups in the total IPSS score, postvoid residual (ml), maximum urine flow rate (ml/s), patient satisfaction with treatment efficacy based on the TS-VAS visual analogue scale (total score). However, we didn’t find significant differences in rate of cardiovascular side effects between the groups.
Conclusions. Treatment of comorbid patients with LUTS/BPH with silodosin at a dose of 8 mg results in significant improvement and is not associated with cardiovascular adverse events.
About the Autors
Corresponding author: A.A. Zimichev – Ph.D., MD, professor at the Department of Urology of FGBOU VO Samara State Medical University, Samara, Russia; e-mail: zimichew@mail.ru
Similar Articles
